Nonsteroidal anti-inflammatory drugs, especially COX-2 inhibitors alone or in combination, have shown the most promise for CRC risk reduction [4], but an increased risk of serious cardiovascular events associated with COX-2 inhibitor use has been reported [5,6]. The gene discussed is PTGS2; the disease is colorectal carcinoma.